Adamis Pharmaceuticals Corp. (ADMP) Shares Down 1.3%
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP)’s share price was down 1.3% during mid-day trading on Tuesday . The stock traded as low as $3.07 and last traded at $3.14, with a volume of 158,634 shares changing hands. The stock had previously closed at $3.18.
Separately, Maxim Group upped their price target on shares of Adamis Pharmaceuticals Corp. from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th.
The firm has a 50-day moving average price of $4.58 and a 200-day moving average price of $5.72. The company’s market cap is $47.27 million.
In other Adamis Pharmaceuticals Corp. news, SVP David J. Marguglio sold 4,860 shares of Adamis Pharmaceuticals Corp. stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $9.17, for a total value of $44,566.20. Following the sale, the senior vice president now directly owns 112,227 shares in the company, valued at approximately $1,029,121.59. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP David J. Marguglio sold 4,000 shares of Adamis Pharmaceuticals Corp. stock in a transaction on Monday, May 16th. The shares were sold at an average price of $8.08, for a total transaction of $32,320.00. Following the completion of the sale, the senior vice president now owns 102,227 shares in the company, valued at $825,994.16. The disclosure for this sale can be found here.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.